Haematologica (Aug 2011)

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

  • Per Ljungman,
  • Rafael de la Camara,
  • Lena Perez-Bercoff,
  • Manuel Abecasis,
  • Jose Bartolo Nieto Campuzano,
  • M. Jimena Cannata-Ortiz,
  • Catherine Cordonnier,
  • Hermann Einsele,
  • Marta Gonzalez-Vicent,
  • Ildefonso Espigado,
  • Jörg Halter,
  • Rodrigo Martino,
  • Bilal Mohty,
  • Gülsan Sucak,
  • Andrew J Ullmann,
  • Lourdes Vázquez,
  • Katherine N. Ward,
  • Dan Engelhard

DOI
https://doi.org/10.3324/haematol.2011.041913
Journal volume & issue
Vol. 96, no. 8

Abstract

Read online

During 2009, a new strain of A/H1N1 influenza appeared and became pandemic. A prospective study was performed to collect data regarding risk factors and outcome of A/H1N1 in hematopoietic stem cell transplant recipients. Only verified pandemic A/H1N1 influenza strains were included: 286 patients were reported, 222 allogeneic and 64 autologous recipients. The median age was 38.3 years and the median time from transplant was 19.4 months. Oseltamivir was administered to 267 patients and 15 patients received zanamivir. One hundred and twenty-five patients (43.7%) were hospitalized. Ninety-three patients (32.5%) developed lower respiratory tract disease. In multivariate analysis, risk factors were age (OR 1.025; 1.01–1.04; P=0.002) and lymphopenia (OR 2.49; 1.33–4.67; P